---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-23-000038"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:34:48.632618+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Moderna Q3 net loss $3.6B on $1.8B revenue; guides 2024 sales ~$4B, aims for 2026 breakeven

## Summary
- Q3 revenues $1.8B, down 44% YoY; net loss $3.6B vs net income $1.0B; diluted EPS -$9.53.
- Non-cash charges of $3.1B: $1.3B inventory write-downs, $0.5B contract manufacturing wind-down, $1.7B tax valuation allowance.
- 2023 product sales guidance at least $6B; 2024 sales projected ~$4B; expects breakeven in 2026.
- COVID-19 U.S. market share rose to 45% (from 36%); RSV vaccine BLA filed with FDA, launch expected 2024.
- Cash and investments $12.8B; plans to fund without raising equity.

## SEC filing metadata
- accession: 0001682852-23-000038
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000038/0001682852-23-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000038/mrna-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-23-000038
- JSON: https://secwatch.observer/filing/0001682852-23-000038.json
- Plain text: https://secwatch.observer/filing/0001682852-23-000038.txt

## Key facts
- Earnings Releases
  Moderna, Inc. reported third quarter ended September 30, 2023 results: revenue $1.8 billion, net income $3.6 billion. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2023
  - Revenue: $1.8 billion
  - Net income: $3.6 billion
  - Guidance: reaffirmed
  - Result: reported results
  source text: Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000038/0001682852-23-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.